Media coverage about Iradimed (NASDAQ:IRMD) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Iradimed earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 44.9230542968609 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Iradimed (NASDAQ IRMD) opened at $15.10 on Monday. The firm has a market cap of $159.38, a P/E ratio of 116.15 and a beta of 1.61. Iradimed has a one year low of $7.85 and a one year high of $15.14.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.35. Iradimed had a net margin of 6.51% and a return on equity of 4.58%. The company had revenue of $5.69 million for the quarter, compared to the consensus estimate of $5.60 million. During the same quarter last year, the firm posted $0.14 earnings per share. Iradimed’s revenue was down 25.9% on a year-over-year basis. analysts predict that Iradimed will post 0.05 earnings per share for the current fiscal year.

Several brokerages have issued reports on IRMD. ValuEngine raised shares of Iradimed from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Roth Capital assumed coverage on shares of Iradimed in a research note on Tuesday, October 31st. They set a “buy” rating and a $16.00 price objective on the stock. Credit Suisse Group assumed coverage on shares of Iradimed in a research note on Monday, November 27th. They set a “buy” rating and a $19.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $15.33.

In other news, Director Monty K. Allen sold 1,898 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $13.95, for a total value of $26,477.10. Following the completion of the sale, the director now owns 9,062 shares of the company’s stock, valued at $126,414.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 60.10% of the stock is owned by corporate insiders.

WARNING: “Iradimed (IRMD) Receiving Somewhat Favorable News Coverage, Analysis Finds” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at

About Iradimed

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with's FREE daily email newsletter.